We are live on
!
Find out more
VCIM
Velan Capital Investment Management Portfolio holdings
AUM
$160M
1-Year Est. Return
517.12%
This Fund
S&P 500
This Quarter
Est. Return
+4.42%
1 Year Est. Return
+517.12%
3 Year Est. Return
+2,524.89%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$107M
AUM Growth
-$67.6M
(-39%)
Cap. Flow
-$56.8M
Cap. Flow
% of AUM
-53.13%
Top 10 Holdings %
Top 10 Hldgs %
92.18%
Holding
23
New
6
Increased
3
Reduced
3
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Liquidia Corp
LQDA
|
+$3.28M |
| 2 |
Corbus Pharmaceuticals
CRBP
|
+$2.56M |
| 3 |
SCPH
scPharmaceuticals
SCPH
|
+$2.5M |
| 4 |
Zevra Therapeutics
ZVRA
|
+$1.36M |
| 5 |
Tenax Therapeutics
TENX
|
+$302K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALIM
Alimera Sciences
ALIM
|
+$75.7M |
| 2 |
Outlook Therapeutics
OTLK
|
+$1.82M |
| 3 |
ELEV
Elevation Oncology
ELEV
|
+$1.61M |
| 4 |
Skye Bioscience
SKYE
|
+$1.18M |
| 5 |
Jasper Therapeutics
JSPR
|
+$758K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 86.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Jasper Therapeutics
JSPR
$26.5M
| $27M | 25.22% |
1,433,828
-38,076
| -3% | -$758K |
|
2
Praxis Precision Medicines
PRAX
$10.2B
| $20.2M | 18.87% |
350,666
| – | – |
|
3
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.4B
| $14.8M | 13.86% |
+150,000
| New | +$14.7M |
|
4
Heron Therapeutics
HRTX
$63.4M
| $13.9M | 13% |
6,986,744
| – | – |
|
|
TRML
5
DELISTED
Tourmaline Bio
TRML
| $8.51M | 7.96% |
331,190
+12,110
| +4% | +$202K |
|
6
Rezolute
RZLT
$450M
| $3.88M | 3.63% |
800,000
| – | – |
|
|
7
Liquidia Corp
LQDA
$8.14B
| $3M | 2.81% |
+300,000
| New | +$3.28M |
|
8
Context Therapeutics
CNTX
$41.9M
| $2.53M | 2.36% |
1,290,323
| – | – |
|
9
InspireMD
NSPR
$37.9M
| $2.42M | 2.27% |
904,029
| – | – |
|
|
SCPH
10
DELISTED
scPharmaceuticals
SCPH
| $2.36M | 2.21% |
+517,668
| New | +$2.5M |
|
11
TELA Bio
TELA
$42.1M
| $1.89M | 1.77% |
747,410
+1,323
| +0.2% | +$4.71K |
|
|
OPTN
12
DELISTED
OptiNose
OPTN
| $1.44M | 1.34% |
143,107
-23,082
| -14% | -$337K |
|
|
13
Zevra Therapeutics
ZVRA
$675M
| $1.39M | 1.3% |
+200,000
| New | +$1.36M |
|
14
Protara Therapeutics
TARA
$230M
| $1.05M | 0.98% |
574,000
+94,000
| +20% | +$193K |
|
|
15
Corbus Pharmaceuticals
CRBP
$177M
| $1.03M | 0.96% |
+50,000
| New | +$2.56M |
|
|
16
Skye Bioscience
SKYE
$18.8M
| $825K | 0.77% |
211,071
-211,071
| -50% | -$1.18M |
|
17
Kiora Pharmaceuticals
KPRX
$11.7M
| $447K | 0.42% |
122,223
| – | – |
|
|
18
Tenax Therapeutics
TENX
$52.4M
| $288K | 0.27% |
+83,333
| New | +$302K |
|
|
ELEV
19
DELISTED
Elevation Oncology
ELEV
| – | – |
-597,299
| Closed | -$1.61M |
|
|
20
Outlook Therapeutics
OTLK
$217M
| – | – |
-247,084
| Closed | -$1.82M |
|
21
X4 Pharmaceuticals
XFOR
$426M
| – | – |
-21,967
| Closed | -$382K |
|
|
ALIM
22
DELISTED
Alimera Sciences
ALIM
| – | – |
-13,608,533
| Closed | -$75.7M |
|
|
ASLN
23
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
| – | – |
-78,125
| Closed | -$188K |
|
Similar funds
BFAG
SLG
SMF
LCA
SA
SGCM
RP
PCC
Velan Capital Investment Management's Q3 2024 Portfolio in Review
As of Q3 2024, Velan Capital Investment Management held 23 positions worth $107M, down 39% from $175M the previous quarter. Its ten largest holdings account for 92% of the portfolio.
Velan Capital Investment Management withdrew a net $56.8M in Q3 2024, closing 5 positions and reducing 3 holdings. Its most notable exit was Alimera Sciences, an estimated $75.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 100% a quarter earlier.
Against the trend, Velan Capital Investment Management opened a new position in Liquidia Corp worth $3M.
- Velan Capital Investment Management's largest Q3 2024 buy was Liquidia Corp: 300,000 shares worth $3M.
- Velan Capital Investment Management added most to Tourmaline Bio in Q3 2024, an estimated $202K increase.
- Velan Capital Investment Management's biggest Q3 2024 reduction was Skye Bioscience, cutting an estimated $1.18M.
- Velan Capital Investment Management fully exited Alimera Sciences in Q3 2024, selling an estimated $75.7M.
- Velan Capital Investment Management's ten largest holdings make up 92% of its $107M portfolio in Q3 2024.
- Velan Capital Investment Management opened 6 new positions and closed 5 in Q3 2024.
- Velan Capital Investment Management's portfolio value fell 39% quarter-over-quarter to $107M.
Based on Velan Capital Investment Management's 13F filing for Q3 2024, filed 14 Nov 2024.